Medtronic (NYSE:MDT) said today that it won breakthrough status from the FDA for its investigational personalized closed-loop insulin pump system.
The company touted its technology as enabling automated insulin delivery in a real-time, adaptable and personalized fashion.
Medtronic’s November acquisition of nutrition data science company Nutrino Health will play a role in the development of its closed-loop insulin pump system, according to the medtech titan.
